Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD

Respiratory Research

Table 1 General characteristics of COPD patients and controls

	Never smoker controls, n = 11	Ex-smoker controls, n = 44	COPD, n = 88
Age	58 ± 5.9	61 ± 5.4	63 ± 8^E,N
Male, (n)%	(3) 27.3	(22) 50	(46) 52.3
Pack years^*	0 ± 0	15.6 ± 13.3	35.0 ± 16.1^E,N
Smoking status, (n)%^§	-	-	Ex-smoker (64) 72.7 Current smoker (18) 20.5
BMI, kg/m²	26.9 ± 4.0	27.52 ± 4.0	26.1 ± 5.2
FEV₁% predicted	114.5 (104.0-120.0	122.1 (112.0-133.0)	45.50 (32.3-61.0)^E,N
FEV₁/VC%	79.2 (74.6-82.3)	78.9 (75.2-82.5)	51.9 (38.3-63.3)^E,N
D_LCO% predicted	-	-	51.46 (42.4-73.19)
LTOT (n)	-	-	16
Triglycerides, mg/dl	92.2 (85.1-109.0)	93.0 (71.8-135.6)	100.1 (84.2-136.9)
HDL, mg/dl	69.1 ± 14.3	68.5 ± 20.5	75 ± 27
CRP, mg/L	0.6 (0.1-0.9)	0.7 (0.3-1.8)	3.4 (1.7-8.5)^E,N
Medication use
Long/short acting muscarinic receptor antagonist (n)%			63 (73.9)
LABA, (n)%			40 (45.5)
SABA, (n)%			23 (26.1)
LABA + inhaled corticosteroids, (n)%			54 (61.4)
Inhaled corticosteroid, (n)%			11 (12.5)
Oral corticosteroid, (n)%			17 (19.3)
N- acetylcysteine, (n)%			9 (10.2)
Statins, (n)%			22 (20.6)

Unless otherwise stated all data are expressed as mean ± SD or median (IQR).
p-value <0.05 between COPD patients and ex-smoking controls is noted as E, and between COPD and never smoking controls as N.
^*indicates history of pack year smoked is missing for 34 patients; smoking stop date is available for this group.
^§indicates smoking status of 6 patients were missing because of missing information on pack years smoked or smoking stop date.
Abbreviations used: BMI, body mass index; FEV₁, forced expiratory volume in 1 second; HDL, high density lipoproteins; CRP, C- reactive protein; LABA, long-acting beta agonists; SABA, short-acting beta agonists.

ISSN: 1465-993X